Berlin antibody firm BioGenes is hoping that its participation in cNeupro, a European initiative to discover protein biomarkers for dementia, will raise its profile abroad.

The deal, for which BioGenes will develop only monoclonal antibodies, will enable the vendor to share ownership of the antibodies with cNeupro, and to pocket royalties on the ones that lead to commercial products.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.